Evidence map›Paper›PMID 31035782›Full record

ArticleJournal of cardiovascular pharmacology and therapeutics2019

Preclinical Evaluation of Safety and Biodistribution of Red Cell Microparticles: A Novel Hemostatic Agent.

Ashish K Rehni, Vibha Shukla, Hever Navarro Quero, Carlos Bidot, Conner R Haase, Ensign Anise A Crane, Shivam G Patel, Sebastian Koch, Yeon S Ahn, Wenche Jy and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cardiovascular pharmacology and therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. The Effect of Extracellular Vesicles on Thrombosis.Journal of cardiovascular translational research · 2023
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ashish K Rehni1 Peritz Scheinberg Cerebral Vascular Disease Research Laboratories, University of Miami Miller School of Medicine, Miami, FL, USA.
Vibha Shukla1 Peritz Scheinberg Cerebral Vascular Disease Research Laboratories, University of Miami Miller School of Medicine, Miami, FL, USA.
Hever Navarro Quero3 Wallace H Coulter Platelet Laboratory, Division of Hematology and Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Carlos Bidot3 Wallace H Coulter Platelet Laboratory, Division of Hematology and Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Conner R Haase1 Peritz Scheinberg Cerebral Vascular Disease Research Laboratories, University of Miami Miller School of Medicine, Miami, FL, USA.
Ensign Anise A Crane1 Peritz Scheinberg Cerebral Vascular Disease Research Laboratories, University of Miami Miller School of Medicine, Miami, FL, USA.
Shivam G Patel1 Peritz Scheinberg Cerebral Vascular Disease Research Laboratories, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID 0000-0002-6776-5206
Sebastian Koch1 Peritz Scheinberg Cerebral Vascular Disease Research Laboratories, University of Miami Miller School of Medicine, Miami, FL, USA.
Yeon S Ahn3 Wallace H Coulter Platelet Laboratory, Division of Hematology and Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Wenche Jy3 Wallace H Coulter Platelet Laboratory, Division of Hematology and Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Kunjan R Dave1 Peritz Scheinberg Cerebral Vascular Disease Research Laboratories, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID 0000-0002-0173-5338

Funding

Red blood cell microparticles (RMPs) to reduce bleeding following hemorrhagic strokeR33NS094896 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI DAVE, KUNJAN R · 2017 to 2018
$835k
Red blood cell microparticles (RMPs) to reduce bleeding following hemorrhagic strokeR21NS094896 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI DAVE, KUNJAN R · 2016 to 2016
$307k
NINDS NIH HHS R21 NS094896NINDS NIH HHS R33 NS094896
6 · The paper itself

Abstract

backgroundUncontrollable bleeding is a major cause of mortality and morbidity worldwide. Effective hemostatic agents are urgently needed. Red cell microparticles (RMPs) are a highly promising hemostatic agent. This study evaluated the safety profile of RMPs preliminary to clinical trial. METHODS AND

resultsRMPs were prepared from type O+ human red blood cell by high-pressure extrusion. Male rats were treated with RMPs either a 1 × bolus, or 4 × or 20 × administered over 60 minutes. The vehicle-treated group was used as a control. Effects on physiological parameters were evaluated; namely, blood pressure, body and head temperature, hematocrit, and blood gases. We did not observe any adverse effects of RMPs on these physiological parameters. In addition, brain, heart, and lungs of rats treated with 4 × dose (bolus followed by infusion over 60 minutes) or vehicle were examined histologically for signs of thrombosis or other indications of toxicity. No thrombosis or indications of toxicity in brain, heart, or lungs were observed. Studies revealed that RMPs were distributed mainly in liver, spleen, and lymph nodes, and were potentially excreted through the kidneys.

conclusionsOur study indicates that RMP administration appears not to have any negative impact on the parameters studied and did not produce thrombosis in heart, brain, and lungs. However, more detailed long-term studies confirming the safety of RMP as a hemostatic agent are warranted.

Indexed as

Erythrocyte TransfusionHemostasisHemostatic TechniquesAnimalsCell-Derived MicroparticlesErythrocytesHumansMaleRats, Sprague-DawleyTime FactorsTissue Distributionbiodistributionbrainheartlungsphysiological parametersthromboembolism

Identifiers

PMID31035782
PMCPMC7745738

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.